Author

Jordi Camps

Universitat Autònoma de BarcelonaORCID 0000-0003-2929-4228Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genomics· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Approach:machine learning (classical)· 2 Research Focus:benchmarking· 1 Research Focus:cell-cell communication· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Antoni CastellsiD· 2 shared Eva Hernández‐IllániD· 2 shared Juan José LozanoiD· 2 shared Darawalee Zong· 1 shared Elena AsensioiD· 1 shared Ferran NadeuiD· 1 shared Iván ArchillaiD· 1 shared Javier del ReyiD· 1 shared

Activity by Year

2019-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenomics

Antoni CastellsORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cell BiologybioRxivPreprintSep 28, 2026

TCF4 and CtBP1 Repress LEF1 to Maintain a TCF4-centric Transcriptional Program in Colon Cancer.

Markus A. Brown, Sanam Yaghoubi, Juliane Kamlah…·Paul S. Meltzer

This study shows TCF4 represses LEF1 to maintain a TCF4-driven transcriptional program in colon cancer, with TCF4 regulating MYC and cell cycle while repressing LEF1's immune-related effects.

DOI 10.64898/2026.09.25.751839

humanbulk RNA-seq

𝕏 PostBluesky

GenomicsbioRxivPreprintApr 16, 2021

Copy-number intratumor heterogeneity contributes to predict relapse in chemotherapy-naive stage II colon cancer

Sara Lahoz, Iván Archilla, Elena Asensio…·Jordi Camps

The paper identifies copy-number intratumor heterogeneity as a predictor of relapse in stage II colon cancer, improving risk prediction beyond clinicopathological markers.

2 citations

humanbulk RNA-seq

𝕏 PostBluesky

GenomicsbioRxivPreprintJul 16, 2019

CNApp: quantification of genomic copy number alterations in cancer and integrative analysis to unravel clinical implications

Sebastià Franch‐Expósito, Laia Bassaganyas, María Vila-Casadesús…·Jordi Camps

CNApp quantifies genomic copy number alterations in cancer and integrates them with clinical and molecular data to identify clinical implications.

DOI 10.1101/479667

humanwhole-genome sequencing

𝕏 PostBluesky